Role of proton MR spectroscopy in the high field magnet (3T) in diagnosis of indeterminate breast masses (BIRDS 3 & 4)  by Razek, Naglaa Mohamed Abdel et al.
The Egyptian Journal of Radiology and Nuclear Medicine (2012) 43, 657–662Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLERole of proton MR spectroscopy in the high ﬁeld magnet
(3T) in diagnosis of indeterminate breast masses (BIRDS
3 & 4)Naglaa Mohamed Abdel Razek a,*, Amr Osama Azab a, Omar Sherif Omar b,
Hussein Osama Soliman ca Radiology Department, Faculty of Medicine, Cairo University, Egypt
b Surgery Department, Faculty of Medicine, Cairo University, Egypt
c Department of Surgery, National Cancer Institute, Cairo University, EgyptReceived 28 May 2012; accepted 3 August 2012
Available online 15 September 2012*
M
E-
Pe
N
03
OpKEYWORDS
MR Spectroscopy;
Indeterminate breast masses;
CholineCorresponding author. Add
ohandseen 1 adan street, Ca
mail address: naglaabdelraze
er review under responsibility
uclear Medicine.
Production an
78-603X  2012 Egyptian So
en access under CC BY-NC-ND lress: Al
iro, Egyp
k@yahoo
of Egyp
d hostin
ciety of
httpicense.Abstract Background: Since 80% of abnormalities found in the breast are benign upon biopsy,
New techniques must provide more precise evaluation of these indeterminate lesions .MR spectros-
copy is one of the available new techniques on MRI, it refers to the measurement of biochemical
compounds in the tissue using specialized sequences.
Purpose: To evaluate the role of MR spectroscopy using the state of the art high ﬁeld magnet
(3 Tesla) as a diagnostic method in indeterminate breast lesions (BIRADS 3 and 4 lesions) aiming
at decreasing the un-necessary breast intervention.
Material & method: In this study 240 female patients classiﬁed as BIRADS 3 & 4 by sono-
mammography (Sono-MX) were examined by MRI using the multiphase dynamic sequence and
proton MR spectroscopy using a high ﬁeld magnet (3 Tesla). Single voxel technique after adequate
shimming was used.
Results: Eighty eight cases (35%) were malignant (based on the presence of high choline peak in
the spectrum) and 152 cases (65%) were benign (no choline peak). MR-spectroscopy has increased
the sensitivity & speciﬁcity of Dynamic MR-Mammography for diagnosis of probable lesion from
93.6% (88/94) and 77.9% (152/195) to 96.7% (88/91) and 95.5% (152/159), False positive results
were found in 4 cases and False negative results were found in 7 cases.fa Scan radiology center in
t. Mobile: +20 1001449957.
.com (N.M.A. Razek).
tian Society of Radiology and
g by Elsevier
Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
://dx.doi.org/10.1016/j.ejrnm.2012.08.003
658 N.M.A. Razek et al.Conclusion: MR Proton spectroscopy in the high ﬁeld magnet (3T) offered additional information
that increased the sensitivity and speciﬁcity of the conventional dynamic MRI in evaluating prob-
able breast lesions and hence reduced the need for unnecessary intervention.
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Since 80% of abnormalities found in the breast are benign
upon biopsy, new techniques must provide more precise eval-
uation of these indeterminate lesions. MRI of the breast pro-
vides a good tool for diagnosis based on the morphological
and the kinetic data. In addition to morphologic and kinetic
analyses, molecular information has been expected to be use-
ful for the diagnosis of breast disease. In vivo proton (1H)
MR spectroscopy (MRS) of the breast, which provides molec-
ular information obtained in a non-invasive manner, has
shown that choline-containing compounds can be detected
in most breast cancers (1,2), whereas choline is generally not
detectable in normal breast tissues. Thus MR spectroscopy
can be helpful in diagnosis of indeterminate lesions based on
the well-established principle that malignant tissues show
elevated concentrations of choline, a product of membrane
synthesis. So elevated choline is considered as marker for
cancer (1,2).
The purpose of this study was to determine the role of MR
H1 spectroscopy using the state of art high ﬁeld magnet
(3 Tesla) as a diagnostic method in indeterminate breast
lesions (BIRADS 3 & 4 lesions) aiming at decreasing the
un-necessary breast intervention.2. Materials and methods
2.1. Patients
This prospective study was approved by our institutional re-
view board. All patients gave written informed consent for
the review of their medical records and images.
Between November 2010 and December 2011, breast MRI
with spectroscopywas performed for 510 patientswith breast dis-
ease at our centre.Among these patients 240were done for assess-
ment of indeterminate and suspicious breast masses, categorized
as BIRADS 3 & BIRADS 4 after sono-mammography. All
cases were females and their age ranged between 32 and
67 years ± 3 years.
The sonomammography studies were available for review
in all cases.
All cases were histopathologically proven after core needle
biopsy (75 cases), vacuum assisted biopsy (54 cases) and open
surgical biopsy for the remaining (111 cases).2.2. MRI
 MRI was performed using a 3T system (Philips Gyroscan
Achieva 3T) using the multiphase dynamic sequence and
proton MR spectroscopy using a high ﬁeld magnet
(3 Tesla)). A double breast coil (four-channel breast array
coil) was used for MRI. Before the administration of contrast material, bilateral
sagittal fat-suppressed T2-weighted images (TR/TE,
4,780/97; ﬁeld of view, 16 cm; matrix, 256 · 256; slice thick-
ness, 3 mm; time of acquisition, 78 s) and coronal T1-
weighted images (8/4.8; ﬂip angle, 25; ﬁeld of view,
33 cm; matrix, 320 · 320; slice thickness, 3 mm; time of
acquisition, 52 s) were obtained.
 Dynamic MRI using a 3D fat-suppressed volumetric inter-
polated breath-hold examination (VIBE) sequence with
parallel acquisition was performed every minute for the
following seven minutes after injection of a bolus of Gadop-
entate dimeglumine (0.1 mmol/kg; Magnevist, Bayer
HealthCare) at a rate of 2 mL/s, followed by a 20-mL saline
ﬂush administered using an automatic injector. Both breasts
were examined in the axial plane at 30 s, 1 min, 2 min, 3 min,
4 min, 5 min and 6 min after contrast injection, respectively.
The parameters for dynamic MRI were as follows: 5.2/2.3;
ﬂip angle, 12; ﬁeld of view, 33 cm; matrix, 448 · 318; recei-
ver bandwidth, 430 Hz per pixel; interpolated slice thick-
ness, 0.9 mm; partitions, 144; and time of acquisition, 60 s.
The right and left breasts were examined in the sagittal plane
using the VIBE sequence with the following parameters (4.0/
2.2; ﬂip angle, 15; ﬁeld of view, 16 cm; matrix, 256 · 256;
receiver bandwidth, 390 Hz per pixel; interpolated slice
thickness, 1.2 mm; partitions, 80; time of acquisition, 60 s).
2.3. 1H MRS
After all the MRI sequences had been performed, single-voxel
1H MRS was performed using a point-resolved spectroscopy
sequence (PRESS). The parameters of MRS were 1,620/270;
voxel size, 15 · 15 · 15 mm3; 256 acquisitions; spectral width,
1,000 Hz; 1,024 data points; and time of acquisition, 7 min.
For voxel placement, coronal and sagittal contrast-enhanced
T1-weighted MR images were used as scout images, and a vox-
el of interest was placed to include the lesion.
Shimming was performed automatically ﬁrst, followed by
manual shimming on the water resonance for optimization
of the homogeneity in each volume of interest. Water-peak line
widths of 10–20 Hz (full width at half-maximum [FWHM])
were typically achieved. After the shimming procedure, spectra
were acquired with water suppression by applying three chem-
ical shift-selective excitation pulses. By spectral suppression
using dual band-selective inversion with gradient dephasing
(3), the transverse magnetization was selectively dephased
before and after the second spin-echo pulse.
3. Data processing and spectral interpretation
3.1. Image interpretation
One radiologist with 9 years of experience in breast MRI
evaluated contrast-enhanced MR images prospectively. For
Fig. 1 (A) Forty-year-old woman with enhancing mass lesion in the 3D MIP reconstructed images after Dynamic multiphase contrast
breast MRI. (B) Forty -year-old woman with enhancing mass lesion. Axial 3D contrast-enhanced fat-suppressed MR image (TR/TE, 4.0/
2.2) at 2.5 min after contrast administration shows enhancing mass and the kinetic data obtained from the lesion shows a type 2 curve
(continuous rise followed by plateau). (C) Forty-year-old woman with enhancing mass lesion. The MRS shows absence of Choline peak in
the spectrum at 3.2 ppm, a sign speaks against breast cancer. It was a true negative case for MRS and the case was histopathologically
proven as ﬁbroadenoma.
Fig. 2 (A) Forty eight-year-old woman with enhancing breast mass. Axial MRI after Dynamic contrast showing the enhancing mass. (B)
Forty eight -year-old woman with enhancing mass lesion in the left breast. The kinetic data obtained from the time intensity curve indicate
a highly suspicious pattern, Type 3 curve was obtained (rapid rise followed by wash out). (C) Forty eight -year-old woman with breast
mass. The MR spectroscopy shows positive Choline peak in the spectrum detected at 3.2 ppm. The lesion was histopathologically proven
as invasive lobular carcinoma.
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660 N.M.A. Razek et al.diagnostic interpretation, the BI-RADS MRI lexicon (4) was
used. Initial enhancement patterns were evaluated .Lesions
were categorized using the interpretation ﬂowcharts of Tozaki
et al. (5) and Fischer’s score (6) for mass and focus and theFig. 3 (A) Female patient 33 years old with left breast non-
palpable lump discovered on her annual screening Mx. The lesion
was categorized as BIRADS 4b. (B) Dynamic Contrast MRI
shows an enhancing small mass. The kinetic data obtained from
the time intensity curve indicate a non-suspicious pattern, type 1
curve (continuous rise not followed by plateau or wash out). (C)
MRS shows high Choline peak detected at 3.2 ppm. A true
positive case for MRS. The lesion was histopathologically proven
as DCIS.interpretation method proposed by Tozaki and Fukuda (7)
and Sakamoto et al. (8) for non-mass like enhancement.
3.2. Spectroscopy interpretation
The spectroscopic data-processing protocol was saved and
linked with the measurement protocol in the software to ensure
that data processing was identical for each measurement. A
Hanning ﬁlter with a window width of 400 ms was applied,
and the Fourier vector was zero-ﬁlled up to 2,048 time points.
We ﬁtted the peaks of choline and water with a gaussian func-
tion from 3.18 to 3.32 ppm for choline and at 4.7 ppm for
water.
Using the residual water signal as a reference (4.7 ppm), a
choline peak at 3.27–3.28 ppm assigned to glycerophospho-
choline, taurine, and myo-inositol was deﬁned as benign, also
absence of choline is assigned as benign (Fig. 1) whereas a peak
resonance at 3.22–3.23 ppm assigned to phosphocholine was
deﬁned as malignant (Figs. 2 and 3). Baseline correction was
not applied. In this study, a threshold signal-to-noise ratio of
2 was used for choline (9,10).
3.3. Statistical analysis
To analyse group differences from dichotomous variables, chi-
square and Fisher’s exact tests were used. The Wilcoxon’s rank
sum test was used to analyse group differences from numeric
variables. A p value less than 0.05 was considered to indicate
a statistically signiﬁcant difference.
4. Results
4.1. Histopathology
The lesions were classiﬁed as a mass lesion in 170 cases, non-
mass lesion in 45 cases, and focal lesion in 25 cases (Table
1). All 240 lesions were included in BIRADS categories 3 &
4, category 3 (n= 80), 4a (n= 60), category 4b (n= 44), or
category 4c (n= 45) (Table 2). The histopathologic diagnosis,
which was established by core biopsy (n= 75), vacuum-
assisted stereotactic biopsy (n= 12), sonography-guided
vacuum-assisted biopsy (n= 42), or excisional biopsy
(n= 111),(Table 3), was a malignant lesion in 88 cases andTable 2 BIRADS category of the study group (n= 240).
BIRADS category No of lesions Percentage
BIRADS 3 80 33.33
BIRADS 4a 60 25
BIRADS 4b 55 22.92
BIRADS 4c 45 18.75
Total 240 100
Table 1 MR-Mammography ﬁndings of the study group
(n= 240).
MR-M Mass Non-mass Focal lesions
240 cases 170 45 25
Table 4 Histopathology of the study group (n= 240).
Pathology Number of lesions Percentages
DCIS 12 5
IDC 58 24
Medullary Ca 5 2.1
Lobular Ca 7 2.9
Colloid Ca 6 2.5
Fibroadenomas 80 33
Papillomas 22 9.1
Sclerosing adenosis with atypia 27 11.3
Proliferative disorder 23 9.6
Total 240 100
Table 5 Performance Evaluation of MRM and MRS in
diagnosis of indeterminate breast lesions (n= 240).
Performance indicators Dynamic MRM (%) MRM and MRS (%)
Sensitivity 93.6 (88/94) 96.7 (88/91)
Speciﬁcity 77.9 (152/195) 95.5 (152/159)
Table 3 The biopsy methods used for histopathology.
Biopsy method No of lesions
CNB 75
VAB 54
OB 111
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category 4a, 4b, and 4c lesions were 18%, 34%, and 95%,
respectively. The average size of the malignant lesions was
26 mm (range, 7–76 mm) and that of the benign lesions was
15 mm (range 5–47 mm).
All patients with a biopsy result of malignancy underwent
mastectomy or breast-conserving surgery. The histologic types
of malignancy included ductal carcinoma in situ (DCIS)
(n= 12); invasive ductal carcinoma, not otherwise speciﬁed
(ductal NOS) (n= 58); invasive lobular carcinoma (n= 7);
medullary carcinoma (n= 5); & colloid carcinoma (n= 6).
The 152 benign lesions included usual ductal hyperplasia with
sclerosing adenosis (n= 27), intraductal papilloma (n= 22),
ﬁbroadenoma (n= 80) & benign proliferative disease
(n= 23).Table 4.
4.2. 1H MRS
The diagnostic sensitivity and speciﬁcity of 1H MRS for the
240 lesions were 96.7% (88/91) and 95.5% (152/159), respec-
tively (p< 0.001) (Table 5). For the Dynamic MR-Mammog-
raphy without spectroscopy, the sensitivity and speciﬁcity were
93.6% (88/94) and 77.9% (152/195), respectively (p<0.001).
The histologic diagnoses of the 4 false-negative mass lesions
by MRS included ductal NOS in 3 cases, mucinous carcinoma
in one case. The negative results could be explained by the
central necrosis. The histologic diagnoses in the seven false-
positive mass lesions by MRS included were ﬁbroadenomasand three of these were found in lactating females. In these
cases the peak of choline was characteristically short & biﬁd.
The false negative lesions by dynamic MRM were 9 cases
and the false positive lesions were 43 cases.
5. Discussion
MR Spectroscopy of the breast is a promising method for
cancer detection. Clinical investigations using breast MR spec-
troscopy have just shown great promise in the MR diagnosis of
breast lesions and in the therapeutic decision for patients with
breast cancers. According to our results, the diagnostic sensi-
tivity and speciﬁcity of 1H MRS done using the 3T high ﬁeld
magnet for the 240 lesions were 96.7% (88/91) and 95.5%
(152/159), respectively (p<0.001). For the Dynamic MR-
Mammography without spectroscopy, the sensitivity and spec-
iﬁcity were 93.6% (88/94) and 77.9% (152/195), respectively
(p<0.001). The false-negative lesions by MRS included 3 duc-
tal NOS masses and one mucinous carcinoma. The negative re-
sults could be explained by the central necrosis. Seven false
positive cases were encountered .The histologic diagnoses in
the seven false-positive mass lesions by MRS included were
ﬁbroadenomas and three of these were found in lactating fe-
males. In these cases the peak of choline was characteristically
short & biﬁd. The false negative lesions by dynamic MRM
were 9 cases and the false positive lesions were 43 cases. These
results were comparable to the previously published (10–12).
Lipnick et al. improved breast cancer detection through the
combination of morphological and enhancement information
from DCE-MRI and metabolic information from 2D MRS.
The sensitivity and speciﬁcity of their combined contrast
enhanced MRI with MRS increased to 92% and 100%, respec-
tively (13).
A meta-analysis by Katz-Brull et al. (2002) showed the
overall combined sensitivity and speciﬁcity of MRS as 83%
and 85%, respectively (14). A sensitivity of 100% and a spec-
iﬁcity of 89–100% in detecting malignancy from benign lesions
were reported using MRS technique (Roebuck et al. 1998; Ce-
cil et al. 2001; Yeung et al. 2001) (15–17).
The results of this study using a 3TMRI unit suggested that
careful referencing and optimizing post acquisition data pro-
cessing improved the spectral resolution resulting in few
false-positive and false negative cases .In the current study,
1H MRS was performed using the residual water signal as a
reference. However, the sensitivity (96.7%; 88/91) was signiﬁ-
cantly higher than that (89%; 149/168) reported in previous
studies of 1.5-T MRI (10).
We believe that one of the major reasons for our higher sen-
sitivity result is the high ﬁeld magnet. In our study there was
no problem with the smaller lesions unlike the previously pub-
lished (10) when 1H MRS was applied to characterize mass le-
sions larger than 15 mm compared to 5 mm lesions, the
diagnostic sensitivity increased from 44% to 82%, whereas
the speciﬁcity decreased from 85% to 69% (10). Therefore, it
is difﬁcult to routinely perform 1H MRS on a 1.5-T MR unit
to characterize breast masses smaller than 15 mm but based on
our results, the potential availability of higher-ﬁeld-strength
magnets will enable us to characterization of smaller breast
lesions by the MRS.
Based on our results we found that 1H MRS was a powerful
method for characterizing indeterminate breast lesions based
662 N.M.A. Razek et al.on the presence of a high choline peak in the spectrum. The
combined assessment of morphologic patterns on contrast-
enhanced MRI and the kinetic data together with the MRS
allows better characterization of indeterminate breast lesions.
6. Conclusion
MR Proton spectroscopy in the high ﬁeld magnet (3T) offered
additional information that increased the sensitivity and
speciﬁcity of the conventional dynamic MRI in evaluating
probable breast lesions & hence reduced the need for unneces-
sary intervention.
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